180 Life Sciences Corp. (NASDAQ:ATNF) Sees Large Growth in Short Interest

180 Life Sciences Corp. (NASDAQ:ATNF) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 61,800 shares, an increase of 309.3% from the February 29th total of 15,100 shares. Currently, 12.2% of the shares of the company are short sold. Based on an average daily trading volume, of 97,600 shares, the days-to-cover ratio is presently 0.6 days.

180 Life Sciences Price Performance

180 Life Sciences stock opened at $2.01 on Thursday. The company’s 50 day moving average price is $3.64 and its two-hundred day moving average price is $6.03. 180 Life Sciences has a 52 week low of $1.80 and a 52 week high of $51.30.

Institutional Investors Weigh In On 180 Life Sciences

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of 180 Life Sciences by 7.9% in the 1st quarter. Vanguard Group Inc. now owns 1,083,744 shares of the company’s stock worth $2,807,000 after purchasing an additional 79,338 shares during the period. Charles Schwab Investment Management Inc. bought a new stake in shares of 180 Life Sciences in the 3rd quarter worth approximately $210,000. Armistice Capital LLC bought a new stake in shares of 180 Life Sciences in the 3rd quarter worth approximately $80,000. Renaissance Technologies LLC raised its holdings in shares of 180 Life Sciences by 138.7% in the 2nd quarter. Renaissance Technologies LLC now owns 115,100 shares of the company’s stock worth $98,000 after purchasing an additional 66,887 shares during the period. Finally, State Street Corp raised its holdings in shares of 180 Life Sciences by 14.0% in the 1st quarter. State Street Corp now owns 73,587 shares of the company’s stock worth $191,000 after purchasing an additional 9,061 shares during the period. Institutional investors own 4.07% of the company’s stock.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.